Lonrho

Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

Retrieved on: 
Thursday, February 22, 2024
Senior, Audit, Compass Group, Immunology, Clotilde Delbos, Emlyon Business School, Henley Business School, Nomination, Duke, Axa, Bucknell University, Interim, Specialization, Therapy, Biology, Committee, Childhood arthritis, RCI Banque, Pechiney, Pandion, GSK plc, PwC, Division, Lonrho, Gilead Sciences, Merlin, Corporate responsibility, Audit committee, Business administration, Duke University, Immune tolerance, Science, Annual, Management

Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

Key Points: 
  • Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
    Paris, February 22, 2024.
  • The Chairman warmly thanked them for their valued contribution to the Board of Directors and the specialized committees to which they belonged during their terms in office.
  • In 2016, Clotilde Delbos was appointed Group Chief Financial Officer and Chairman of Board of Directors of RCI Banque.
  • “The arrivals of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy will strengthen the Board of Directors’ expertise in finance and science, notably in the field of immunology.

Global Acute Myeloid Leukemia (AML) Treatment Market Trends and Forecasts, 2020-2022 & 2023-2028 with Profiles of Major Players - AbbVie, Daiichi Sankyo, GlaxoSmithKline, Pfizer and Servier - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Pharmaceutical, Health, Oncology, Incidence, Mortality, Haematopoietic system, GSK plc, Pfizer, Growth, Daiichi Sankyo, Risk, COVID-19, DSM-IV codes, Radiation, Anthracycline, Bone marrow, Lonrho, AbbVie, AML, Pharmaceutical industry, Vaccine, Dentistry, Laboratoires Servier

The "Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering.
  • The global AML treatment market was valued at nearly $3.5 billion in 2022.
  • This study's primary objective is to conduct a comprehensive analysis of the AML treatment market, offering insights into its dynamics, prevailing trends, and the overall market landscape.
  • Technological advancements in the field of blood cancer have played a pivotal role in propelling the AML treatment market forward.

E-commerce Reshapes the Consumer Healthcare Landscape, Driving a 6.90% CAGR in Market Value Through 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 12, 2023
Vitamins, Supplements, Cannabis, Telemedicine, Virtual Medicine, Health, Pharmaceutical, General Health, Retail, Natural Resources, Online Retail, Pain, COVID-19, OTC, Hypertension, BASF, Death, Research, Inflammation, Pfizer, GSK plc, Dementia, BASF SE, Bayer, Safety, Cancer, Diabetes, Procter & Gamble, Heart, Mental health, Ageing, SE, Growth, Life expectancy, Lonrho, Amway, Malpractice, Vitamin, Sleep, Sanofi, Arthritis, Patient, Infection, Pharmaceutical industry, CBD

As a result, the elderly population requires proper healthcare and treatment, which has directly propelled the consumer healthcare market.

Key Points: 
  • As a result, the elderly population requires proper healthcare and treatment, which has directly propelled the consumer healthcare market.
  • Manufacturers may be held responsible for such misuse, creating a challenge for the consumer healthcare market.
  • The consumer healthcare industry witnessed increased demand during the COVID-19 pandemic, driven by the essential need for healthcare products worldwide.
  • The integration of technology with healthcare is expected to further enhance the consumer healthcare market in the coming years.

Global Adult Vaccines Market Research Report 2023: Market to Surpass $25 Billion by 2027 - Long-term Forecasts to 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 11, 2023
Health, Pharmaceutical, Measles, DPT, Research report, Hepatitis, COVID-19, Hospital, Acquisition, Food, Vaccine, Tuberculosis, Traction, Prevalence, Meningococcal vaccine, GSK plc, SARS, Infection, World Health Organization's response to the COVID-19 pandemic, Simplex, World Health Organization, Shingles, Merck, Growth, Statistics, Lonrho, Merck & Co., Tetanus, Regulation of tobacco by the U.S. Food and Drug Administration, Sanofi, Messenger, Streptococcus, Research, Themis

Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.

Key Points: 
  • Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.
  • The adult vaccines market research report is an invaluable resource, offering a wealth of statistics on the adult vaccines market, including global market size, regional distributions, insights into market competitors with their respective market shares, comprehensive segmentation of the adult vaccines market, prevailing market trends, and promising opportunities.
  • These alarming statistics underscore the pivotal role of adult vaccines in curbing the spread of contagious diseases and substantiate the burgeoning growth of the adult vaccines market.
  • The adult vaccines market encompasses the sales of mRNA vaccines and viral vector vaccines.

Pathward, Dash Solutions Extend Partnership and Take on Untapped Disbursements Market with Real-Time Payment Solutions

Retrieved on: 
Wednesday, August 2, 2023
Finance, Banking, Payments, Professional Services, Technology, Partnership, Digital, Multimedia, Dash, ACH, Lonrho, Apple, Growth, SMS, Renewable energy, Online shopping, Bank

“Our partnership with fintechs has exponential power to solve tough challenges with large-scale programs that create greater flexibility, accessibility and inclusion in our financial system.

Key Points: 
  • “Our partnership with fintechs has exponential power to solve tough challenges with large-scale programs that create greater flexibility, accessibility and inclusion in our financial system.
  • We are pleased to partner with Dash Solutions for the rollout of SpendIT SendIT.
  • Dash Solutions addresses the growing market demand for real-time, frictionless disbursements to consumers and should reduce the administrative costs of the payout process for companies making payment.
  • “Our partnership with Pathward continues to energize our team,” said Stephen Faust, CEO of Dash Solutions.

Global Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems Analysis Report 2023-2028 Featuring Major Players - Bristol-Myers Squibb, Camurus, GlaxoSmithKline, Merck & Novartis

Retrieved on: 
Thursday, June 29, 2023
Nanoparticle, GSK plc, Drug development, Face, Administration, COVID-19, Clinical trial, Quality of life, Lonrho, Research, Forecasting, Patent, Patient, Bristol-Myers Squibb Co. v. Superior Court, Ecosystem, Health, Environment, Nanotechnology, Novartis, Fine chemical, Pharmaceutical industry, Medical imaging, Biotechnology, Camurus

DUBLIN, June 29, 2023 /PRNewswire/ -- The "Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 29, 2023 /PRNewswire/ -- The "Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.
  • The most rapid advances have been made in the application of nanoparticles in drug research and development, drug formulation, and the development of novel drug delivery systems using nanoparticle carriers.
  • The size and shape of nanoparticles is an important aspect to determine their properties and influences the drug performance and efficacy on the body.
  • Drug formulation and drug delivery systems are major application areas that are lucrative for startups in Europe, thus contributing to the market's growth.

Directorate change

Retrieved on: 
Tuesday, May 9, 2023
Acacia, AIM, Lonrho, PwC, Audit committee, BDO, ACA, Gold, Risk, SRB, Cooper, TSX, Audit

Ms Gudgeon qualified as an ACA accountant at PwC (Coopers & Lybrand) before spending eight years as Finance Executive with the Africa-focused mining and trading group Lonrho plc.

Key Points: 
  • Ms Gudgeon qualified as an ACA accountant at PwC (Coopers & Lybrand) before spending eight years as Finance Executive with the Africa-focused mining and trading group Lonrho plc.
  • Ms Gudgeon subsequently held positions with Deloitte, BDO, Gazelle Corporate Finance and Penfida Limited.
  • As well as being an independent non-executive director, Ms Gudgeon is or was also chair of the audit committee for each of these entities.
  • “I am delighted to have Deborah join the Board of Directors of the Company as an independent Non-executive Director.

Aseptic Fill Finish Global Market Report 2023: Growing Demand for Aseptic Fill Finish Services Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 11, 2023
Chemicals, Plastics, Manufacturing, Molecule, Vaccine, APL, Charles River Laboratories, Hetero Drugs, Partnership, Fresenius (company), Patheon, Powder, Lonrho, Overalls, Research, Antibody, Type, Organization, Zenith Contract Services, Protein, Risk, Peptide, Approved Drug Products with Therapeutic Equivalence Evaluations, WuXi Biologics, Health, Robotics, Intas Pharmaceuticals, Oligonucleotide, Safety, Syringe, Fine chemical, Marketing, Glass, Airline, Oil

The report features an extensive study of the current market landscape and future opportunity for the aseptic fill finish service providers.

Key Points: 
  • The report features an extensive study of the current market landscape and future opportunity for the aseptic fill finish service providers.
  • In fact, a number of companies are involved in offering biologics fill finish services and small molecule fill finish services.
  • Answer: The global aseptic fill finish services market is expected to grow at a CAGR of 7%, during the period 2023-2035.
  • Answer: Presently, the vials (67%) account for the largest share in the global aseptic fill finish services market.

Jubilant HollisterStier Announces New President and Upcoming Availability of Expanded Production Capacity for Sterile Injectables

Retrieved on: 
Thursday, March 16, 2023
Research, Medical Devices, Medical Supplies, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Lonrho, Jubilant, Furman University, University, Business, Widener University Commonwealth Law School, Partnership, Darla Moore School of Business, Journal of International Business Studies, USD, JHS, Government, Wharton School of the University of Pennsylvania, Marketing, GSK plc, Privacy and the US government, Pharmaceutical industry, Pharma, Chemistry

Jubilant HollisterStier (JHS), a leading US-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products announces the appointment of Chris Preti as President.

Key Points: 
  • Jubilant HollisterStier (JHS), a leading US-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products announces the appointment of Chris Preti as President.
  • Chris Preti has 25 years of varied pharmaceutical experience in research and development, marketing and sales, and operations, including positions of increasing responsibility at Glaxo SmithKline and HollisterStier Allergy, where he was most recently President.
  • As previously announced in May 2022, Jubilant HollisterStier’s expansion plan that is investing ~285 million (USD) to double its capacity for fill and finish of sterile injectables at its Spokane, Washington facility, is progressing well.
  • Chris Preti commented, “This is an exciting time to join Jubilant HollisterStier, as the company continues to expand its capacity to address growing industry demand for the high-quality services we provide.

SpyBiotech Appoints Industry Veteran Eddie Gray as Chair of its Board of Directors

Retrieved on: 
Monday, February 13, 2023
Oncology, Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, MBA, Independent, Infection, Corporation, European Pharmaceutical Students' Association, Patient, VLP, Government of the United Kingdom, GSK plc, Lonrho, Eddie, Grey, Hepatitis B, Knowledge, IPSO, Independent Press Standards Organisation, FDA, HPV Prevention and Control Board, Conditional sentence, Cancer, Vaccine, Pharmaceutical industry

SpyBiotech , a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Eddie Gray, MBA, as Chairman of its Board of Directors.

Key Points: 
  • SpyBiotech , a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Eddie Gray, MBA, as Chairman of its Board of Directors.
  • Gray joins the Board as an independent director.
  • He is a Board member of The Independent Press Standards Organisation (IPSO), the UK press regulatory body.
  • “I am excited to join SpyBio’s Board of Directors as Chair as the company progresses its first vaccine candidate into the clinic,” said Eddie Gray.